XFOR X4 Pharmaceuticals, Inc.
$3.25▲ +0.00%
Healthcare
Other
After hours
$3.25▲ +0.00%
Oct 27, 4:47 PM ET
Volume 1.61M
Avg Volume (10D) 609.6K
Key Metrics & Fundamentals
Market Cap
$322.23M
P/E Ratio
162.5
Div Yield
0.00%
52W Range
2.43 - 4.83
% vs 50 MA
-3.66%
% vs 200 MA
-14.66%
RSI-14
57.3
MACD Histogram
+0.1000
Beta (1Y vs SPY)
1.54
Free Cash Flow
-$25.79M
Gross Rev
$8.81M
Gross Profit
$7.19M
EBITDA
-$13.52M
COGS
$1.62M
Operating Exp
$23.58M
Operating Income
-$16.39M
EBIT
-$16.39M
Pretax Income
-$16.16M
Net Income
-$16.16M
EPS (Diluted)
-0.13
Price & Volume History
Loading chart…
Recent News
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
GlobeNewswire · Oct 9, 2026 7:00 AM ET
X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures
InvestorsHub · Oct 8, 2026 8:30 AM ET
X4 Pharmaceuticals Enters Up to $150 Million Term Loan Facility
MT Newswires · Oct 8, 2026 7:54 AM ET
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
GlobeNewswire · Oct 8, 2026 7:00 AM ET
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 1, 2026 4:30 PM ET
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
Zacks · Sep 24, 2026 8:35 AM ET
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · Sep 11, 2026 9:35 AM ET
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
GlobeNewswire · Sep 9, 2026 7:00 AM ET
X4 Pharmaceuticals Reaches FDA Agreement on Revised Phase 3 Trial for Chronic Neutropenia Treatment
MT Newswires · Sep 8, 2026 8:18 AM ET
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
GlobeNewswire · Sep 8, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See XFOR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.